St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping
July 27, 2011
St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping
Approximately 85 percent of a 51-member panel at the St. Gallen International Breast Cancer Conference supported the use of Oncotype DX to help decide which patients should receive chemotherapy.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- In Preliminary Recommendation, UK's NICE Backs Oncotype DX in Subset of Breast Cancer Patients
February 20, 2013 / Pharmacogenomics Reporter - Economic Model Finds MammaPrint More Cost-Effective than Oncotype; Highlights Need for Future Studies
May 9, 2012 / Pharmacogenomics Reporter - After Moving MammaPrint to FFPE Format, Agendia Sees Revenue Boost, Increasing Adoption
April 25, 2012 / Pharmacogenomics Reporter - Breast Cancer Test Makers Will Attempt to Sway UK's NICE in Wake of Initial Negative Opinion
February 8, 2012 / Pharmacogenomics Reporter - NanoString Study Suggests PAM50 Recurrence Test Provides Advantages over Oncotype DX
December 14, 2011 / Pharmacogenomics Reporter